To explore a recently established association between histaminergic and dopaminergic neuronal phenotypic systems in brain, we determined the effect of the respective histaminergic H3 receptor agonist and antagonist/inverse agonist, imetit and thioperamide, on L-DOPA - derived tissue and extracellular dopamine (DA) and metabolite levels in the striatum of 6-hydroxydopamine (6-OHDA) - lesioned rats (i.e., parkinsonian rats). We also examined the influence of histamine H3 ligands on L-DOPA evoked behavioral responses (locomotor activity, number of rearings, stereotyped behavior and motor coordination). Using HPLC/ED and in vivo microdialysis technique, imetit (5 mg/kg, i.p.) but not thioperamide (5 mg/kg, i.p.) was shown to attenuate an L-DOPA-evoked (15 mg/ kg, i.p.; carbidopa, 30 min pretreatment) increase in extracellular DA in the neostriatum of 6-OHDA-lesioned rats. However, both imetit and thioperamide increased microdialysate levels of DOPAC and HVA, probably by enhancing intraneuronal DA utilization. As indicated by neurochemical analysis of the striatum imetit produced a decrease in tissue DA content. These findings support the hypothesis that central H3 histaminergic receptors have a modulatory role in the storage, metabolism and release of DA derived from exogenous L-DOPA challenge. Furthermore, evidence from behavioral studies indicate that histamine H3 receptor block markedly improved motor coordination. Conversely, histamine H3 receptor stimulation, being without effect on motor coordination, enhanced vertical activity in rats. From the above we conclude that histamine H3 agonism may augment motor dyskinesia in Parkinson's disease (PD) patients and presumably worsen L-DOPA therapy. Consequently, the histaminergic system represents a viable target for modulating the effectiveness of L-DOPA therapy in Parkinson's disease.

Neonatal administration of quinpirole produces significant increases in D2 receptor sensitivity that persists into adulthood. This phenomenon, known as D2 receptor priming, is consistent with pathology in schizophrenia. Rats were administered quinpirole or saline postnatally and raised to adulthood. In adulthood, rats were administered d-amphetamine sulfate or saline every other day and were placed in a locomotor arena where activity was measured over 7 trials. Results showed that D2-primed rats receiving amphetamine were higher in locomotor activity across all days of testing compared to other groups. This effect was more prominent in males than in females. After sensitization, cerebrospinal fluid was taken via microdialysis from the nucleus accumbens core and was analyzed for dopamine content. Analysis revealed D2 priming produced a 300% increase of dopamine release in the nucleus accumbens core in response to amphetamine compared to controls. These results suggest that increases in D2 sensitivity may lead to increased reaction to amphetamine in psychotic individuals.

No description available.

Passive permeability of drug molecules through biological membranes is a fundamentally important process that involves the partitioning of molecules into the lipid bilayer membrane and passive permeation across the membrane. The majority of the drug molecules are either weak bases or acids. For these drugs, along with lipophilicity and other physicochemical properties, the acid/base nature and ionization constant (pKa) are very important for predicting their passive permeation across biological barriers. Depending on the pKa of ionizable groups, drug molecules may coexist in various biological fluids both their charged and uncharged forms to varying extents. According to the widely known pH-partition hypothesis, only the uncharged form of ionizable molecules contributes to the passive permeability. Therefore, permeability and absorption rate should be proportional to the molar fraction of the uncharged form in the bulk medium. However, there is ample evidence of deviations from this linear relationship manifesting in nonlinear passive permeability vs fraction unionized plots. It is possible that the assumption of a constant pKa for ionizable drugs contributes to many of these cases of apparent deviations which cannot be explained by other factors such as paracellular or active transport. Studies have provided evidence for pKa shifts of ionizable drugs when partitioned into different bilayer lipid membrane systems.It is thought that electrostatic interaction between the membrane partitioned charged solutes and phospholipid charged headgroups contributes to the pKa shift (apparent pKa) which can change the uncharged fraction in the membrane interface causing a proportional change in the passive permeation rate from the expected rate predicted with an aqueous pKa. This would appear as a violation of the pH-partition hypothesis when other contributing factors can be ruled out. Therefore, a surrogate membrane phospholipid system (DAPC/n-hexane) was employed to investigate potential pKa shifts following interaction between phospholipid charged headgroups and ionizable drugs. Several probe drugs of acidic, basic and neutral nature were investigated with this biphasic surrogate system with controls at different aqueous pH levels to determine their apparent pKa values. The partitioning of compounds into membranes can be thought of as an integral part of membrane permeability. Extensive partitioning of drug molecules into the intracellular membranes which constitute the majority of all the cell membranes potentially results in the observed lag phase in monolayer permeability assays. Hepatocyte drug binding correlates strongly with microsomal drug binding suggests that binding to cells is presumably a result of non-specific drug partitioning into membranes. For this reason, cellular drug distribution equilibrium in the cells might not be achieved instantaneously, as is often assumed in permeability models and perfusion-limited PBPK models. Therefore, characterization of this early distribution phase by observing the time course of the free drug concentration in drug-spiked cell suspensions (MDCK & rat hepatocyte) was pursued with a novel in vitro microdialysis approach followed by in silico investigations with mathematical modeling. Depending on the drug, the apparent pKa values in the surrogate membrane system at different pH levels indicate significant shift from the inherent pKa values of the ionizable probe drugs. The in vitro microdialysis technique allowed the determination of the time course of free drug concentration in MDCK and rat hepatocyte cell suspensions spiked with probe drugs with high temporal resolution. Two mechanistic models developed with intracellular membrane compartment along with lysosomal or mitochondrial ion-trapping compartment resulted in excellent model fitting for the observed time-course data in MDCK cell and rat hepatocyte suspensions for tolbutamide and metoprolol, respectively. / Pharmaceutical Sciences

Bone healing involves a variety of different cell types and biological processes. Although certain key molecules have been identified, the molecular interactions of the healing progress are not completely understood. Moreover, a clinical routine for predicting the quality of bone healing after a fracture in an early phase is missing. This is mainly due to a lack of techniques to comprehensively screen for cytokines, growth factors and metabolites at their local site of action. Since all soluble molecules of interest are present in the fracture hematoma, its in-depth assessment could reveal potential markers for the monitoring of bone healing. Here, we describe an approach for sampling and quantification of cytokines and metabolites by using microdialysis, combined with solid phase extractions of proteins from wound fluids. By using a control group with an isolated soft tissue wound, we could reveal several bone defect-specific molecular features. In bone defect dialysates the neutrophil chemoattractants CXCL1, CXCL2 and CXCL3 were quantified with either a higher or earlier response compared to dialysate from soft tissue wound. Moreover, by analyzing downstream adaptions of the cells on protein level and focusing on early immune response, several proteins involved in the immune cell migration and activity could be identified to be specific for the bone defect group, e.g. immune modulators, proteases and their corresponding inhibitors. Additionally, the metabolite screening revealed different profiles between the bone defect group and the control group. In summary, we identified potential biomarkers to indicate imbalanced healing progress on all levels of analysis.

La dépression est une pathologie grave qui, malgré de multiples stratégies thérapeutiques, demeure résistante chez un tiers des patients. Les techniques de stimulation cérébrale sont devenues une alternative intéressante pour les patients résistants à diverses pharmacothérapies. La stimulation du nerf vague (SNV) a ainsi fait preuve de son efficacité en clinique et a récemment été approuvée comme traitement additif pour la dépression résistante. Cependant, les mécanismes d’action de la SNV en rapport avec la dépression n’ont été que peu étudiés. Cette thèse a donc eu comme premier objectif de caractériser l’impact de la SNV sur les différents systèmes monoaminergiques impliqués dans la pathophysiologie de la dépression, à savoir la sérotonine (5-HT), la noradrénaline (NA) et la dopamine (DA), grâce à l’utilisation de techniques électrophysiologiques et de la microdialyse in vivo chez le rat. Des études précliniques avaient déjà révélé qu’une heure de SNV augmente le taux de décharge des neurones NA du locus coeruleus, et que 14 jours de stimulation sont nécessaires pour observer un effet comparable sur les neurones 5-HT. Notre travail a démontré que la SNV modifie aussi le mode de décharge des neurones NA qui présente davantage de bouffées, influençant ainsi la libération terminale de NA, qui est significativement augmentée dans le cortex préfrontal et l’hippocampe après 14 jours. L’augmentation de la neurotransmission NA s’est également manifestée par une élévation de l’activation tonique des récepteurs postsynaptiques α2-adrénergiques de l’hippocampe. Après lésion des neurones NA, nous avons montré que l’effet de la SNV sur les neurones 5-HT était indirect, et médié par le système NA, via l’activation des récepteurs α1-adrénergiques présents sur les neurones du raphé. Aussi, tel que les antidépresseurs classiques, la SNV augmente l’activation tonique des hétérorécepteurs pyramidaux 5-HT1A, dont on connait le rôle clé dans la réponse thérapeutique aux antidépresseurs. Par ailleurs, nous avons constaté que malgré une diminution de l’activité électrique des neurones DA de l’aire tegmentale ventrale, la SNV induit une augmentation de la DA extracellulaire dans le cortex préfrontal et particulièrement dans le noyau accumbens, lequel joue un rôle important dans les comportements de récompense et l’hédonie. Un deuxième objectif a été de caractériser les paramètres optimaux de SNV agissant sur la dépression, en utilisant comme indicateur le taux de décharge des neurones 5-HT. Des modalités de stimulation moins intenses se sont avérées aussi efficaces que les stimulations standards pour augmenter l’activité électrique des neurones 5-HT. Ces nouveaux paramètres de stimulation pourraient s’avérer bénéfiques en clinique, chez des patients ayant déjà répondu à la SNV. Ils pourraient minimiser les effets secondaires reliés aux périodes de stimulation et améliorer ainsi la qualité de vie des patients. Ainsi, ces travaux de thèse ont caractérisé l’influence de la SNV sur les trois systèmes monoaminergiques, laquelle s’avère en partie distincte de celle des antidépresseurs classiques tout en contribuant à son efficacité en clinique. D’autre part, les modalités de stimulation que nous avons définies seraient intéressantes à tester chez des patients recevant la SNV, car elles devraient contribuer à l’amélioration des bénéfices cliniques de cette thérapie. / Depression is a severe psychiatric disorder, in which a third of patients do not achieve remission, despite the wide variety of therapeutic strategies that are currently available. Brain stimulation has emerged as a promising alternative therapy in cases of treatment resistance. Vagus nerve stimulation (VNS) has shown promise in treating resistant-depressed patients, and it has been approved as an adjunctive treatment for resistant depression. However, the mechanism of action by which VNS exerts its antidepressant effects has remained elusive. The first goal of this thesis was therefore to characterize the impact of VNS on monoaminergic systems known to be implicated in the pathophysiology of depression such as serotonin (5-HT), norepinephrine (NE) and dopamine (DA), by means of electrophysiologic techniques and microdialysis in the rat brain. Previous research has indicated that one hour of VNS increased the basal firing activity of locus coeruleus NE neurons and, secondarily, that of 5-HT neurons, but only after 14 days of stimulation. Our work demonstrated that VNS also modified the firing pattern of NE neurons towards a bursting mode of discharge. This mode of firing was shown to lead to enhanced NE release in the prefrontal cortex and hippocampus after 14 days. Increased NE neurotransmission was also evidenced by enhanced tonic activation of postsynaptic α2-adrenoceptors in the hippocampus. Selective lesioning of NE neurons was then used to demonstrate that the effects of VNS on the 5-HT system were indirect, and mediated by the activation of α1-adrenoceptors located on the dorsal raphe 5-HT neurons. Similar to classical antidepressants, VNS also enhanced the tonic activation of pyramidal 5-HT1A heteroreceptors, which are known to play a key role in the antidepressant response. We also found that in spite of a diminished firing activity of ventral tegmental area DA neurons after VNS, extracellular DA levels were significantly elevated in the prefrontal cortex, and particularly in the nucleus accumbens which plays an important role in reward behavior and hedonia. A second objective was to characterize the optimal VNS parameters to treat depression using the firing activity of 5-HT neurons as an indicator. It was found that less stimulation was as effective as the standard levels to increase 5-HT neurons firing rate. These novel parameters could be helpful for clinical application in VNS responsive patients, to potentially minimize and/or even prevent stimulation-related side effects, thus improving their quality of life. In brief, these studies reveal an influence of VNS on all three central monoamine systems, which differs in part from that of classical antidepressants while contributing to the clinical efficacy of this approach. It will also be interesting to determine whether the proposed lower stimulation parameters are as effective in providing antidepressant response in patients receiving VNS, which should contribute to improve the clinical benefits of that therapy.

Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Analytical Chemistry Candidate: Ivo Vrobel Supervisors: Prof. RNDr. Petr Solich, CSc; Department of Analytical Chemistry, Faculty of Pharmacy, Charles University in Prague Prof. Seppo Auriola, MSc.(Chem.) Marko Lehtonen; Department of Pharmaceutical Chemistry, School of Pharmacy, University of Eastern Finland in Kuopio Title of master's thesis: LC-MS/MS analysis of acetylcholine in brain microdialysis samples Novel fast and simple LC-MS/MS method of ACh quantification in brain microdialysis samples utilizing stable-isotope-labeled IS was developed. The chromatographic step is based on revered-phase mode of pentafluorophenylpropyl (PFPP) column. The satisfactory retention of ACh is achieved with highly aqueous mobile phase containing 0.05% of the ion-pairing agent TFA and 4% of ACN in 4 min analytical run. Ionization of ACh and IS with low background noise and tolerant towards use of TFA was performed with atmospheric pressure thermospray ionization (APTSI). The selectivity of ACh and IS detection was obtained by SRM modes of MS/MS in the linear ion trap mass analyzer. The performance of developed method was cross validated to the validated method used in the laboratory for ACh measurements. The set of microdialysis...

Tout d’abord, nous avons démontré l’origine périphérique de la corticostérone après l’administration d’un stress aigu. Pour cela, nous avons utilisé un modèle de souris déficient en transporteur de corticostérone : Corticosterone binding-globulin (Cbg-/-). Ensuite, nous avons déterminé si les effets rapides du stress sur le rappel mnésique dépendaient de mécanismes non-génomiques. Nous avons précisé si ces effets étaient médiés par les récepteurs aux minéralocorticoïdes (MR) ou aux glucocorticoïdes de l’hippocampe. Dans ce but dans un premier temps, nous avons injecté un complexe macromoléculaire de corticostérone (Cort-3CMO-BSA) qui ne franchit pas la membrane cellulaire pour évaluer l’implication de mécanismes membranaires. Dans un deuxième temps nous avons administré dans l’hippocampe dorsal (HD) ou ventral (HV), 15 minutes avant le stress, l’antagoniste MR (RU 28318) et l’antagoniste GR (RU 38486) et nous avons évalué les performances mnésiques à 15, 60, 105 et 120 minutes après le stress. En effet ces délais ont été choisis selon l’apparition de pics de corticostérone induit par le stress, mesurés par microdialyse, dans l’HD et l’HV.Les principaux résultats obtenus sont : i) les souris Cbg -/- ne présentent pas de déficit mnésique 15 min après l’administration d’un stress aigu, contrairement aux souris contrôles qui ont un déficit mnésique important; ii) De même, l’administration de métyrapone (un inhibiteur de synthèse de la corticostérone) prévient des effets rapides du stress sur la mémoire; iii) Nous avons démontré que les effets rapides délétères sont médiés par des récepteurs membranaires, puisque l’injection de Cort-3CMO-BSA dans l’HD produit des effets similaires au stress aigu. De plus, l’effet de l’injection du complexe Cort-3CMO-BSA n’est pas bloqué par l’injection systémique d’anisomycine (un inhibiteur de synthèse protéique) nous avons montré que les récepteurs membranaires aux glucocorticoïdes de type MR sont responsables des effets cognitifs rapides du stress et de la cort-3CMO-BSA sur le rappel mnésique ;iv) Dans l’HD, l’injection du RU 28318 bloquait les effets délétères du stress quand les performances mnésiques étaient évaluées 15 min après le stress, mais non aux délais plus longs. Au contraire, le RU 38486 prévenait les déficits mnésiques quand les performances étaient évaluées à 60 mais non à 105 min après le stress. Dans l’HV, le schéma opposé est observé puisque l’injection du RU 38486 est dénuée d’effet quand il est injecté à 60 min après le stress mais il bloque les déficits mnésiques induits 105 min après le stress. L’implication des récepteurs MR et GR et l’efficacité de leur antagoniste semble dépendant de l’évolution de la concentration de corticostérone au cours du temps dans l’HD et l’HV.Pour conclure, notre étude a mis en évidence que le stress aigu diminue le rappel mnésique hipocampo-dépendant par l’intermédiaire d’un mécanisme de “switch” impliquant les récepteurs MR puis GR de l’HD à des délais plus courts et ensuite seulement les récepteurs GR de l’HV à des délais plus long. / We first showed the peripheral origin of corticosterone after an acute stress administration (electric foot-shocks) using corticosterone binding globulin-deficient mice (Cbg -/-). Then, we intended to determine if the rapid effects of stress on memory retrieval depended on non-genomic mechanisms and in a further step to precise whether such effects are mediated by mineralocorticoid (MR) or glucocorticoid receptors (GR) in the hippocampus. To that aims, we first injected a macromolecular complex of corticosterone (Cort-3CMO-BSA) that cannot cross the cell membrane to assess the involvement of membrane mechanisms. In a second step, we injected 15 minutes before stress delivery either in the dorsal (DH) or ventral (VH) hippocampus the MR antagonist (RU 28318) and GR antagonist (RU 38486) and evaluated memory at 15, 60, 105 and 120 minutes after stress delivery. Indeed, these delays were chosen according to the occurrence of stress-induced corticosterone peaks measured by microdialysis in DH and VH.The main results obtained in this study are: i) Cbg -/- mice are not affected by stress delivery occurring 15 minutes before memory testing, in contrast wild-type control mice which exhibited an important memory retrieval deficit; ii) Similarly, the rapid effects of stress on memory could be prevented by the systemic injection of metyrapone (a corticosterone synthesis inhibitor); iii) We showed that the rapid (15min) deleterious of stress on memory are mediated by membrane receptors, since the injection of Cort-3CMO-BSA in the DH produced similar effects as stress delivery. Moreover, the effect of the Cort-3CMO-BSA complex is not blocked by systemic injection of anisomycin (a protein synthesis inhibitor); iv) In DH, the injection of RU 28318 blocked the deleterious effects of stress when testing occurred 15 min after stress but not for longer delays. In contrast, RU 38486 prevented memory retrieval impairments when performance was evaluated at 60 but not at 105 min after stress. In addition, the opposite pattern was observed in VH since RU 38486 was denied of any effects when injected at 60 min but blocked the stress-induced memory impairments at the 105 min post-stress delay. The involvement of MR and GR receptors and consequently the efficiency of their antagonists seem to depend on the time-course evolutions of stress-induced corticosterone rises within the DH and VH.In conclusion, our study evidenced that acute stress impairs hippocampus-dependent memory retrieval via a switch mechanism involving the MR then GR in DH at shorter delays and then only GR in VH at longer delay.

Dans mes travaux de thèse, je me suis intéressé à la fonction de la barrière hémato-encéphalique (BHE) et son impact dans le développement de médicaments à visée du système nerveux central (SNC). Cependant, plusieurs obstacles limitant le processus de développement de nouveaux médicaments ont été identifiés. Parmi eux, une faible biodisponibilité cérébrale est reconnue pour être un facteur limitant majeur. Malgré ce constat, la biodisponibilité et la pharmacodynamie cérébrales sont souvent inconnues ou globalement négligées durant le processus de développement des médicaments. Actuellement, 3 méthodes permettent d'explorer la pharmacocinétique cérébrale in vivo, à savoir l'analyse du liquide céphalorachidien, la tomographie par émission de positron et la microdialyse cérébrale. Chaque approche présente certaines contraintes, la première fournit des informations restreintes, la seconde est coûteuse et limitée à une utilisation principalement académique, la troisième est souvent réalisée sur des modèles rongeurs rendant la transposabilité des données à l’homme complexe. Le projet de recherche réalisé s’est articulé autour de cette problématique et a suivi deux axes de développement. Le premier s’est orienté sur l’étude du passage dans le contexte particulier de la maladie de Parkinson. Le second aborde le manque de modèles pertinents utilisables lors du développement d’un nouveau médicament et présente une solution possible, la microdialyse intracérébrale sur macaque vigile. Les études en lien avec la maladie de Parkinson ont mis en évidence que premièrement, les statines sont inefficace dans le traitement des dyskinésies lévodopa induites chez les patients parkinsoniens. Cet échec peut être en partie explicable par une biodisponibilité cérébrale insuffisante du principe actif. Deuxièmement, la fonction de BHE est modifiée sur le modèle de référence de la maladie de Parkinson, le macaque traité au 1-méthyle 4-phényl 1,2,3,6-tétrahydro pyridine (MPTP). Le travail réalisé selon le second axe démontre la faisabilité de l’échantillonnage du liquide extracellulaire cérébral sur macaque vigile par microdialyse. / While working on my thesis, I focused on the function of the blood-brain barrier (BBB) and its impact in drug development to target the central nervous system (CNS). However, several obstacles that slow down the process of developing new successful drugs have been identified. Among several factors, the poor brain bioavailability is acknowledged as a primary limiting factor. Despite this statement, both brain bioavailability and brain pharmacodynamic are either unknown or globally overlooked during the drug development process. Currently, 3 methods allow exploring in vivo brain pharmacokinetic: cerebral spinal fluid sampling analysis, Positron Emission Tomography imaging and brain microdialysis. Each approach has its own constraints, the first provides restricted information, the second is expensive and limited to a mainly academic use, and the third is often carried out on rodent models making the transferability of data in complex man. The research project is focused on this issue and followed two paths of development. The first is focused on the study of the crossing in the particular context of Parkinson's disease. The second addresses the lack of appropriate model used in the development of a new drug and presents a possible solution, intracerebral microdialysis in awake macaque. Studies linked with Parkinson's disease show that statins has proved ineffective in the treatment of levodopa-induced dyskinesia in parkinsonian patients. This failure can be explained in part by insufficient brain bioavailability of the active compound. Secondly, in macaques treated with 1-methyl 4-phenyl 1,2,3,6-tetrahydro pyridine (MPTP), the gold standard model of Parkinson's disease, the BBB is modified. The work done along the second axis shows the feasibility of sampling brain extracellular fluid by microdialysis in awake macaque.

OLIVEIRA, A.R. Envolvimento de receptores dopaminérgicos da área tegmental ventral e do complexo basolateral da amígdala na aquisição e na expressão do medo condicionado. 2010. 93 f. Tese (Doutorado) Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo. O condicionamento Pavloviano é um dos paradigmas mais utilizados para estudar as bases biológicas das emoções, assim como da aprendizagem e memória. A dopamina (DA) é um dos principais neurotransmissores envolvidos na mediação de estados de medo e ansiedade. Um conjunto crescente de evidências dá suporte à hipótese de que a ativação da via mesocorticolímbica, proveniente de neurônios dopaminérgicos da área tegmental ventral (ATV), é particularmente sensível à estimulação aversiva. Entre as regiões inervadas por esta via, o complexo basolateral da amígdala (BLA) é um componente essencial dos circuitos neurais do medo condicionado. Assim, o presente estudo explorou o envolvimento de mecanismos DA da ATV e do BLA, através do uso de agonistas e antagonistas de receptores DA, na aquisição e expressão do medo condicionado à luz. Não houve efeito das drogas DA no sobressalto potencializado pelo medo (SPM), quando injetadas na ATV antes do condicionamento, indicando que os receptores DA da ATV não participam da aquisição do medo condicionado à luz. Ao contrário, quando injetado na ATV antes do teste, quimpirole (agonista D2) reduziu o SPM, enquanto as demais drogas não tiveram efeito. A administração de SCH 23390 (antagonista D1) no BLA não produziu efeitos no SPM, indicando que os receptores D1 do BLA não parecem envolvidos na expressão do SPM. Já a administração de sulpirida (antagonista D2) no BLA inibiu o SPM produzido pela luz. Além disso, a expressão do medo condicionado foi associada a um aumento do congelamento e dos níveis extracelulares de DA no BLA, ambos inibidos com a administração de quimpirole na ATV. A capacidade do quimpirole em diminuir o SPM e o congelamento condicionado parece ser resultado de sua ação em auto-receptores D2 da ATV. A ativação desses receptores diminui os níveis de dopamina em áreas que recebem terminações da via mesocorticolímbica. Os resultados com a sulpirida realçam a importância dos receptores D2 do BLA na expressão do medo condicionado Pavloviano. / OLIVEIRA, A.R. Involvement of dopaminergic receptors of ventral tegmental area and basolateral amygdala in the acquisition and expression of conditioned fear. 2010. 93 p. Thesis (Doctoral) Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo. The Pavlovian fear conditioning is one of the most used paradigms to study the biological basis of emotion, as well as of learning and memory. Dopamine (DA) is one of the most important neurotransmitters involved in mechanisms underlying states of fear and anxiety. A growing body of evidence supports the hypothesis that excitation of the mesocorticolimbic pathway, originating from DA neurons in the ventral tegmental area (VTA), is particularly sensitive to fear-arousing stimuli. Among the forebrain regions innervated by this pathway, the basolateral amygdala (BLA) is an essential component of the neural circuitry of conditioned fear. The present study explored the involvement of VTA and BLA DA receptors, using DA agonists and antagonists, in the acquisition and expression of conditioned fear to a light conditioned stimulus (CS). None of the drugs used produced significant effects on fear-potentiated startle (FPS) when injected in VTA before conditioning, indicating that VTA DA receptors are not involved in the acquisition of conditioned fear to a light-CS. In contrast, when injected before the test session, intra-VTA quinpirole (D2 agonist) significantly reduced FPS, whereas the other drugs had no effect. Intra-BLA SCH 23390 (D1 antagonist) did not produce significant effects on FPS, indicating that BLA D1 receptors do not appear to be involved in the expression of FPS. On the other hand, intra-BLA sulpiride (D2 antagonist) inhibited FPS produced by light-CS previously paired with footshocks. Also, conditioned fear was associated with increased freezing and DA levels in the BLA, both inhibited by intra-VTA quinpirole. Quinpirole\'s ability to decrease FPS and conditioned freezing may be the result of an action on VTA D2 presynaptic autoreceptors. The activation of those receptors decreases dopamine levels in terminal fields of the mesocorticolimbic pathway. Sulpirides results stress the importance of BLA D2 receptors in the fear-activating effects of the Pavlovian conditioning.